Last updated: 05/20/2026 15:11:51
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.AtDvance
EudraCT ID
Not applicable
EU CT Number
Trial status
Terminated (halted prematurely)
Terminated (halted prematurely)
Trial overview
Official title: Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.
Trial description: The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Non-randomized
Primary outcomes:
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to Week 59
Number of participants with TEAEs leading to permanent discontinuation
Timeframe: Up to Week 59
Number of participants with Serious adverse events (SAEs)
Timeframe: Up to Week 59
Number of participants with Treatment Emergent adverse events of special interest (TEAESI)
Timeframe: Up to Week 59
Secondary outcomes:
Number of Participants Who Achieved Investigators Global Assessment (IGA) response (IGA score of 0 or 1 and a Reduction of greater than or equal to [>=]2 points from Baseline) at Weeks 16, 32, and 48
Timeframe: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Number of participants Who Achieved reduction of greater than or equal to (>=) 75 percent (%) in Eczema Area and Severity Index (EASI) Score from Baseline at Weeks 16, 32 and 48
Timeframe: Baseline (Day 1 from the parent study), Weeks 16, 32 and 48
Number of participants who achieved Reduction of >=4 points in Peak Pruritus Numerical Rating Scale (PP-NRS) Score from Baseline at Weeks 16, 32, and 48
Timeframe: Baseline (Day -7 to Day -1 from the parent study), Weeks 16, 32, and 48
Number of participants Who maintained IGA response (IGA score of 0 or 1 and a Reduction of >=2 points from Baseline) at Weeks 16, 32, and 48
Timeframe: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Number of participants Who maintained response of reduction of >= 75% in EASI Score from Baseline at Weeks 16, 32, and 48
Timeframe: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Percent change from Baseline (CFB) in EASI Score at Weeks 16, 32, and 48
Timeframe: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Interventions:
Drug: GSK1070806
Drug: Placebo
Enrollment:
79
Observational study model:
Not applicable
Primary completion date:
2025-29-07
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Dermatitis, Atopic
Product
GSK1070806
Collaborators
Not applicable
Study date(s)
June 2024 to July 2025
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Participants must sign and date the consent document.
- Participants diagnosed with moderate to severe Atopic dermatitis (AtD) who have completed the qualifying Phase 2 parent study (NCT05999799) of GlaxoSmithKline (GSK's) AtD and, in their opinion, may benefit from GSK1070806.
- Permanent discontinuation of the study drug at any time during GSK's qualifying Phase 2 AtD (NCT05999799) or a medical condition that would hinder GSK's participation in the Phase 2 219538 (NCT05999799) AtD research project.
- Participants who, during GSK's qualifying Phase 2 (NCT05999799) AtD research project, developed adverse event (AE) or Serious adverse event (SAE) based on laboratory parameters, physical examination, vital signs, Electrocardiogram (ECG), medical history, etc. Medical history, in the opinion of the researchers, suggests that if Investigational medicinal product (IMP) is continued, it may cause unnecessary risk to the participants.
Inclusion and exclusion criteria
Inclusion criteria:
- Participants must sign and date the consent document.
- Participants diagnosed with moderate to severe Atopic dermatitis (AtD) who have completed the qualifying Phase 2 parent study (NCT05999799) of GlaxoSmithKline (GSK's) AtD and, in their opinion, may benefit from GSK1070806.
- Be intentional and able to visit the doctor at the clinic by appointment and follow all procedures related to research studies and questionnaires (able to read and understand Patient-reported outcomes (PRO) questionnaires and be able to use electronic devices).
- The use of contraceptive methods for females should be consistent with local regulations on contraceptive methods of participants participating in clinical research programs.
- Female participants are eligible to participate in the research program if they are not pregnant or breastfeeding and meet one of the following conditions:
- It is Woman of nonchildbearing potential (WONCBP).
- It is Woman of childbearing potential (WOCBP) and uses a highly effective contraceptive method that has a failure rate less than (<) 1 percent (%) during the trial dose period and for at least 16 weeks after the last dose of the research drug. We should assess the likelihood of contraceptive failure (e.g., non-cooperation, early contraception) associated with the first dose of the drug.
- WOCBP must obtain a negative result in a highly sensitive pregnancy test (by urine or serum test, as prescribed by local regulations) before receiving the first dose of the research drug.
- If the urine test is positive, or the negative result cannot be confirmed (i.e., the result is unclear), a pregnancy test by serum test is required. In such cases, If the serum is tested, the test result is positive. Participants must be excluded from the research project.
- Additional requirements for testing pregnancy during and after exposure to the drug.
- The researcher is responsible for examining medical history, menstrual cycle history, and sexual activity in the near term. To reduce the risk of screening pregnant women who may not be detected at the beginning of pregnancy.
Exclusion criteria:
- Permanent discontinuation of the study drug at any time during GSK's qualifying Phase 2 AtD (NCT05999799) or a medical condition that would hinder GSK's participation in the Phase 2 219538 (NCT05999799) AtD research project.
- Participants who, during GSK's qualifying Phase 2 (NCT05999799) AtD research project, developed adverse event (AE) or Serious adverse event (SAE) based on laboratory parameters, physical examination, vital signs, Electrocardiogram (ECG), medical history, etc. Medical history, in the opinion of the researchers, suggests that if Investigational medicinal product (IMP) is continued, it may cause unnecessary risk to the participants.
- Topical medications for AtD within 1 week prior to your appointment at Day 1, such as: Topical calcineurin inhibitors (TCI)/ Topical corticosteroids (TCS), Phosphodiesterase-4 (PDE-4) and Janus activation kinase inhibitors (JAKi) for external use.
- Topical corticosteroids (TCS) (such as hydrocortisone, betamethasone)
- Topical calcineurin inhibitors (TCI) (such as tacrolimus, pimecrolimus)
- Phosphodiesterase-4 (PDE4) inhibitor for external use (e.g., crisaborole)
- JAKi for external use (e.g. ruxolitinib)
- Medications for topical use, or other herbal/traditional medicines that may affect the AtD that the participants are in.
- Participant who received systemic therapy, which is considered contraindicated, including systemic therapy used as a rescue medication for AtD, from the screening for GSK's Phase 2 AtD 219538 research project until the LTE protocol began, were unable to participate in the research project.
- Chronic uncontrolled diseases that may require immediate oral corticosteroids, such as severe uncontrolled asthma (defined as having an Asthma control questionnaire (ACQ)-5 score greater than or equal to (>=) of 1.5 or a history of asthma exacerbations. >= 2 times within the last 12 months, requiring systemic corticosteroid [oral and/or intravenous medication] or requiring a >-24-hour hospital stay)
- Experience participating in previous/current clinical research projects.
- The participants have participated in any other clinical research studies. This is in addition to GSK's Phase 2 219538 (NCT05999799) research project.
Trial location(s)
Location
GSK Investigational Site
Springville, UT, Unmapped, 84663
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Canoga Park, CA, Unmapped, 91303
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ciudad Autonoma de Bueno, Argentina, C1056ABI
Status
Study Complete
Location
GSK Investigational Site
North Little Rock, AR, Unmapped, 72117
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Thomasville, GA, Unmapped, 31792
Status
Terminated/Withdrawn
Study documents
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Terminated (halted prematurely)
Actual primary completion date
2025-29-07
Actual study completion date
2025-29-07
Plain language summaries
Summary of results in plain language
Available language(s): English, Bulgarian, Czech, French, German, Greek, Italian, Japanese, Korean, Polish, Chinese (Simplified), Spanish (Argentina), Spanish (Mexico), Spanish (Panama), Spanish, Spanish (United States), Thai
To view plain language summaries on trialsummaries.com click here.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website